<DOC>
	<DOCNO>NCT01819428</DOCNO>
	<brief_summary>The purpose open-label , single-arm , multi-center phase II trial evaluate efficacy safety novel pan-HER inhibitor , NOV120101 ( Poziotinib ) , first-line monotherapeutic agent patient lung adenocarcinoma harbor EGFR mutation .</brief_summary>
	<brief_title>NOV120101 ( Poziotinib ) 1st Line Monotherapy Patients With Lung Adenocarcinoma</brief_title>
	<detailed_description>EGFR TKIs know effective less toxic medication EGFR mutate tumor . However , newly acquire resistance inhibitor inevitable obstacle continuous treatment . To overcome problem , many new class TKIs include NOV120101 ( Poziotinib ) develop day . To evaluate efficacy NOV120101 ( Poziotinib ) first-line monotherapeutic medication , chemotherapy-na√Øve patient participate study . Subjects receive NOV120101 ( Poziotinib ) 12 mg PO daily disease progression unacceptable toxicity development . Objective response rate ( ORR ) analyze primary endpoint trial . Secondary endpoint include PFS rate 12 month , DCR , PFS , OS also analyze .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>1 . Male female patient age 20 year old 2 . Pathologically confirm stage IIIB ( unresectable ) IV lung adenocarcinoma 3 . Documented EGFR mutation ( e.g. , exon 19 deletion , exon 21 L858R , etc . ) tumor tissue 4 . Patients 1 measurable lesion accord RECIST version 1.1 5 . ECOG performance status 2 less 6 . Life expectancy 12 week 7 . Patients adequate hematological , hepatic renal function ; WBC 4,000 per mm3 , platelet 100,000 per mm3 , serum creatinine 1.5 time less upper limit normal , AST ALT 2.5 time less upper limit normal , total bilirubin 1.5 time less upper limit normal 8 . Patients give write informed consent voluntarily 1 . Prior systemic chemotherapy , immunotherapy biological therapy stage IIIB IV adenocarcinoma ( However , neo adjuvant chemo , chemoradio radiotherapy permit least 6 month elapse prior disease progression ) 2 . Prior treatment small molecule antibody target EGFR 3 . Patients receive major surgery within 4 week study drug administration 4 . Symptomatic CNS metastasis ( patient radiologically neurologically stable metastasis corticosteroid least 2 week able participate trial . ) 5 . History malignancy except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure investigator 's judgment 6 . Known preexist interstitial lung disease ( ILD ) 7 . NYHA class III IV heart failure , uncontrolled hypertension , unstable angina myocardial infarction within 6 month , poorly control arrhythmia clinically significant cardiovascular abnormality investigator 's discretion 8 . Patients whose left ventricle ejection fraction ( LVEF ) institutional low limit normal ( low limit normal define site , low limit 50 percent ) 9 . Patients know active hepatitis B , HIV infection , uncontrolled infectious disease 10 . Clinically significant recent acute gastrointestinal disorder diarrhea major symptom ( e.g. , Crohn 's disease , malabsorption disorder , CTCAE grade 2 diarrhea due etiology ) 11 . Patients receive IP mouth diagnose clinically significant gastrointestinal disorder prevent administration , transit absorption study drug 12 . Pregnancy breast feed 13 . Women childbearing potential ( WOCBP ) men unwilling use adequate contraception abstinent trial least 2 month end treatment 14 . Patients receive investigational product except gefitinib erlotinib within 4 week participation 15 . Patients participate trial investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>EGFR mutation</keyword>
	<keyword>Lung Adenocarcinoma</keyword>
	<keyword>Firstline therapy</keyword>
	<keyword>Second generation tyrosine kinase</keyword>
</DOC>